(Reuters) -Indian drugmaker Zydus Lifesciences reported first-quarter profit above estimates on Tuesday, driven by new drug launches in the U.S., its biggest market.

The company posted a 3.3% rise in consolidated net profit to 14.67 billion rupees ($167.4 million) for the quarter ended June 30, beating analysts’ estimates of 13.25 billion rupees, per data compiled by LSEG.

Overall revenue climbed nearly 6%, led by a 3% sales growth in the U.S. and a 6% jump in India.

KEY CONTEXT

Most Indian generic drugmakers, including Zydus Life, which earn a large share of their revenue from the U.S., have been grappling with weak pricing due to intense competition.

However, new products, particularly in the specialty portfolio, have driven Zydus Life’s growth in the United States since the beginni

See Full Page